PROGRAMMABLE TYPE V RNA ENDONUCLEESE SYSTEMS
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- BAYER AG
- Filing Date
- 2022-06-09
- Publication Date
- 2026-07-08
AI Technical Summary
Existing CRISPR-Cas systems face challenges such as large size, limited activity in eukaryotic cells, off-target effects, immune response, complex RNA requirements, and size constraints for viral delivery, which hinder their use in gene therapy and other precise applications.
Development of novel Type V CRISPR Cas nucleases (B-GEn.1 and B-GEn.2) with optimized sgRNAs and reduced RNA synthesis burden, allowing for efficient targeting and editing in eukaryotic cells with improved specificity and reduced off-target activity.
The novel CRISPR Cas nucleases enable precise gene editing in eukaryotic cells with enhanced specificity and reduced RNA requirements, overcoming size constraints and off-target issues, making them suitable for therapeutic applications.